Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy with WT1 peptide and pertussis whole cell vaccine in castration-resistant prostate cancer
jRCTs061180084Phase 2Completed
- Sponsor
- NEC Corporation
- Start
- Mar 2009
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1 peptide and bordetella pertussis whole cell vaccine in prostate cancer (PCa), sponsored by NEC Corporation. Primary endpoints: Safety and side effects (phase I) and Progression-free survival (phase II). Started Mar 2009; status: completed.
02
Drugs
WT1 peptidebordetella pertussis whole cell vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs061180084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180084.